Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Vaccines. 2016;15(3):349-65. doi: 10.1586/14760584.2016.1129905. Epub 2016 Jan 8.

HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.

Author information

1
a Department of Medical Microbiology, Academic Medical Center , University of Amsterdam , Amsterdam , The Netherlands.
2
b Department of Microbiology and Immunology , Weill Medical College of Cornell University , New York , NY , USA.

Abstract

The long pursuit for a vaccine against human immunodeficiency virus 1 (HIV-1) has recently been boosted by a number of exciting developments. An HIV-1 subunit vaccine ideally should elicit potent broadly neutralizing antibodies (bNAbs), but raising bNAbs by vaccination has proved extremely difficult because of the characteristics of the HIV-1 envelope glycoprotein complex (Env). However, the isolation of bNAbs from HIV-1-infected patients demonstrates that the human humoral immune system is capable of making such antibodies. Therefore, a focus of HIV-1 vaccinology is the elicitation of bNAbs by engineered immunogens and by using vaccination strategies aimed at mimicking the bNAb maturation pathways in HIV-infected patients. Important clues can also be taken from the successful subunit vaccines against hepatitis B virus and human papillomavirus. Here, we review the different types of HIV-1 immunogens and vaccination strategies that are being explored in the search for an HIV-1 vaccine that induces bNAbs.

KEYWORDS:

HIV-1; broadly neutralizing antibodies; envelope glycoprotein; immunogen design; nanoparticle vaccines; sequential vaccination; vaccination strategies; vaccines

PMID:
26654478
DOI:
10.1586/14760584.2016.1129905
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center